Replimune Group, Inc.
REPLNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$261.6M | −$234.8M | −$177.1M | −$118.3M | −$80.0M | −$56.2M |
| Net income | −$247.3M | −$215.8M | −$174.3M | −$118.0M | −$80.9M | −$52.6M |
| Total assets | $551.3M | $487.7M | $646.6M | $461.2M | $543.1M | $234.1M |
| Total liabilities | $135.5M | $113.2M | $91.3M | $50.0M | $44.4M | $50.4M |
| Equity | $415.8M | $374.5M | $555.3M | $411.2M | $498.7M | $183.7M |
| EPS (diluted) | $-3.07 | $-3.24 | $-2.99 | $-2.26 | $-1.75 | — |
| Shares out. | 77.1M | 61.4M | 57.8M | 49.1M | 46.6M | 36.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −59.5%
- Return on assets
- −44.9%
- Return on capital (ROCE)
- −53.5%
- Liabilities / assets
- 24.6%
- Debt / equity
- 0.33×
- Book value / share
- $5.39
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.42distress
- Accruals / assets
- −10.0%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2025-09Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
- Phase 1Active Not Recruitingreadout ~2026-10-31Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
- Phase 1Active Not Recruitingreadout ~2026-11-30Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
- Phase 2Recruitingreadout ~2027-12-01Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Phase 2Active Not Recruitingreadout ~2028-06Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
- Phase 3Recruitingreadout ~2029-01-01VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- Phase 1/2Active Not Recruitingreadout ~2029-07Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
- Phase 2/3Recruitingreadout ~2030-01A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ridgeback Capital Investments L.P.Passive (13G)May 21, 2026
- Rtw Investments, LpPassive (13G)May 15, 2026
- Suvretta Capital Management, LlcPassive (13G)May 12, 2026
- Price T Rowe Associates Inc /Md/Passive (13G)May 7, 2026
- Forbion Capital Fund Iii Cooperatief U.A.Passive (13G)Feb 17, 2026
- Redmile Group, LlcPassive (13G)Nov 14, 2025
- Point72 Asset Management, L.P.Passive (13G)Nov 14, 2025
- Baker Bros. Advisors LpActivist (13D)Mar 7, 2025
- Vanguard Group IncPassive (13G)Jan 31, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Xynos KonstantinosOfficer — Chief Medical Officer | May 18, 2026 | Sell | 14,023 | $5.08 |
| Schwendenman AndrewOfficer — Chief Accounting Officer | May 18, 2026 | Sell | 7,894 | $5.08 |
| Sarchi ChristopherOfficer — Chief Commercial Officer | May 18, 2026 | Sell | 8,626 | $5.08 |
| Astley-Sparke PhilipDirector | May 18, 2026 | Sell | 17,657 | $5.08 |
| Patel SushilOfficer — Chief Executive Officer | May 18, 2026 | Sell | 37,324 | $5.08 |
| Hill Emily LuisaOfficer — Chief Financial Officer | May 18, 2026 | Sell | 7,812 | $5.08 |
| Sarchi ChristopherOfficer — Chief Commercial Officer | Apr 1, 2026 | Grant | 50,000 | $0.00 |
| Astley-Sparke PhilipDirector | Apr 1, 2026 | Grant | 50,000 | $0.00 |
| Xynos KonstantinosOfficer — Chief Medical Officer | Apr 1, 2026 | Grant | 50,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 23.7M | 2.8 | +11.8% |
| Apr 30, 2026 | 21.2M | 2.6 | +14.8% |
| Apr 15, 2026 | 18.4M | 1.4 | +12.8% |
| Mar 31, 2026 | 16.3M | 10.5 | +0.7% |
| Mar 13, 2026 | 16.2M | 9.7 | +2.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 29, 2026
- Regulation FD disclosure · Other material eventApr 13, 2026
- Entered a material agreement · Results of operations · New financial obligationFeb 3, 2026
- Regulation FD disclosureJan 12, 2026
- Results of operationsNov 6, 2025
- Other material eventOct 20, 2025
- Regulation FD disclosure · Other material eventSep 18, 2025
- Shareholder vote · Regulation FD disclosureSep 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KMay 29, 2026
- SCHEDULE 13GMay 21, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 12, 2026
- SCHEDULE 13G/AMay 7, 2026
- 8-KFORM 8-KApr 13, 2026
- 4Apr 7, 2026
- 4OWNERSHIP DOCUMENTApr 7, 2026
- 4OWNERSHIP DOCUMENTApr 7, 2026